Pharmaceutical - Takeda Pharmaceutical

Filter

Current filters:

Takeda Pharmaceutical

Popular Filters

1 to 25 of 28 results

Japan’s Takeda optimizes global production network

27-11-2014

Takeda Pharmaceutical has decided to focus its Osaka plant (Osaka Prefecture, Japan) to become a specialty…

GermanyJapanLupronOncologyPharmaceuticalProductionTakeda Pharmaceutical

Takeda US president quits

21-11-2014

The president of Japanese drug major Takeda Pharmaceutical’s (TYO: 4502) US subsidiary, Douglas Cole,…

BoardroomManagementPharmaceuticalTakeda PharmaceuticalUSA

Takeda joins forces with GE Healthcare on liver disease research

Takeda joins forces with GE Healthcare on liver disease research

13-11-2014

Japan’s largest drugmaker Takeda Pharmaceutical has entered into an alliance agreement with UK-based…

GE HealthcareJapanNephrology and HepatologyPharmaceuticalResearchTakeda Pharmaceutical

District Court sets accelerated date to resolve Takeda suit against FDA over Colcrys

District Court sets accelerated date to resolve Takeda suit against FDA over Colcrys

10-11-2014

The US District Court for the District of Columbia, presiding in a law suit between Japanese drugmaker…

ColcrysGastro-intestinalsHikmaLegalPharmaceuticalTakeda PharmaceuticalUSAWest-Ward

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

Added benefit of Takeda’s Entyvio is not proven, says IQWiG

04-11-2014

In an early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products,…

EntyvioGastro-intestinalsGermanyPharmaceuticalPricingRegulationTakeda Pharmaceutical

Russian approval for Norgine/Takeda’s MoviPrep

28-10-2014

Netherlands-headquartered independent drugmaker Norgine says that its partner, Japan’s largest pharma…

Gastro-intestinalsMoviPrepNorginePharmaceuticalRegulationRussiaTakeda Pharmaceutical

Takeda and Lilly’s fine is reduced in Actos case

Takeda and Lilly’s fine is reduced in Actos case

28-10-2014

A US district court has reduced the damages to be paid by Japan’s largest drugmaker Takeda Pharmaceutical…

ActosDiabetesEli LillyLegalPharmaceuticalTakeda PharmaceuticalUSA

Takeda gains exclusive rights to Amitiza beyond US and Canada

Takeda gains exclusive rights to Amitiza beyond US and Canada

23-10-2014

US biopharma company Sucampo Pharmaceuticals saw its shares rise 5.6% to $8.46 in morning trading, after…

AmitizaGastro-intestinalsGlobalLicensingPharmaceuticalSucampoTakeda Pharmaceutical

Orexigen earns total $100 million milestone on Contrave

Orexigen earns total $100 million milestone on Contrave

15-10-2014

US biopharma company Orexigen Therapeutics says it has earned a $70 million milestone payment from partner…

ContraveFinancialMarkets & MarketingMetabolicsOrexigen TherapeuticsPharmaceuticalTakeda PharmaceuticalUSA

Takeda appoints John Boslego as senior vice president of its global vaccine business unit

Takeda appoints John Boslego as senior vice president of its global vaccine business unit

08-10-2014

Japan’s largest drugmaker Takeda Pharmaceutical has appointed John Boslego as senior vice president…

Anti-viralsBoardroomJapanPharmaceuticalTakeda Pharmaceutical

Takeda responds to verdict in US Actos case; invests in vaccines firm

Takeda responds to verdict in US Actos case; invests in vaccines firm

06-10-2014

The US subsidiary of Japan’s largest drugmaker Takeda Pharmaceuticals says that in the case of Frances…

ActosAlfresa CorpDiabetesJapanLegalMergers & AcquisitionsPharmaceuticalTakeda PharmaceuticalUSAVaccine Safe CoVaccines

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

Japan’s non-Hodgkin lymphoma market to exceed $1 billion by 2020

26-09-2014

The non-Hodgkin lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia,…

AdcetrisAustraliaChinaGazyvaroIndiaJapanMarkets & MarketingOncologyPharmaceuticalRocheTakeda Pharmaceutical

Takeda and BioMotiv in strategic partnership, including investment

Takeda and BioMotiv in strategic partnership, including investment

25-09-2014

Japan’s largest drugmaker Takeda Pharmaceutical has made a strategic investment in USA-based BioMotiv,…

BioMotivCardio-vascularFinancialImmunologicalsInflammatory diseasesJapanPharmaceuticalResearchTakeda PharmaceuticalUSA

Meiji and Takeda to co-promote Rozerem for insomnia

Meiji and Takeda to co-promote Rozerem for insomnia

08-09-2014

Fellow Japanese drugmakers Meiji Seika Pharma and Takeda Pharmaceutical have finalized a co-promotion…

JapanLicensingMeiji Seika PharmaNeurologicalPharmaceuticalRozeremTakeda Pharmaceutical

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

Takeda and Lilly fail to overturn $9 billion award for hiding cancer risk of Actos

31-08-2014

Japan’s largest drugmaker Takeda Pharmaceutical and US pharma major Eli Lilly have failed in their…

ActosDiabetesEli LillyFinancialLegalPharmaceuticalTakeda PharmaceuticalUSA

Takeda launches first gut-selective treatment for inflammatory bowel disease in the UK

Takeda launches first gut-selective treatment for inflammatory bowel disease in the UK

28-08-2014

The first gut-selective treatment for ulcerative colitis and Crohn’s Disease is now available in the…

Crohn's diseaseEntyvioGastro-intestinalsInflammatory bowel diseasePharmaceuticalRegulationTakeda PharmaceuticalUKUlcerative colitis

Seven pharma companies offer up compounds to UK researchers

Seven pharma companies offer up compounds to UK researchers

22-07-2014

UK researchers will be granted access to a ‘virtual library’ of deprioritized pharmaceutical compounds…

AstraZenecaEli LillyGlaxoSmithKlineJanssenMedical Research CouncilPfizerPharmaceuticalResearchTakeda PharmaceuticalUCBUK

Highlights of EMA Pharmacovigilance committee July meeting

Highlights of EMA Pharmacovigilance committee July meeting

14-07-2014

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) concluded two safety…

bromocriptineEuropeNephrology and HepatologyNeurologicalPharmaceuticalRegulationRiensoTakeda Pharmaceuticalvalproate Sodium InjectionWomen's Health

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

Third-party investigation confirms Takeda’s systematic involvement in CASE-J Study, but no data tampering

23-06-2014

Japan’s largest drugmaker Takeda Pharmaceuticals has updated on the third-party surrounding the results…

BlopressCardio-vascularJapanMarkets & MarketingPharmaceuticalResearchTakeda Pharmaceutical

Takeda halts development of orteronel for prostate cancer

Takeda halts development of orteronel for prostate cancer

19-06-2014

Japan’s largest drugmaker Takeda Pharmaceutical says that it has voluntarily decided to end the development…

OncologyorteronelPharmaceuticalResearchTakeda Pharmaceutical

Takelda combination tablets now available in Japan

Takelda combination tablets now available in Japan

13-06-2014

Japan’s largest drugmaker Takeda Pharmaceutical says that Takelda, a fixed-dose combination (FDC) of…

Gastro-intestinalsJapanMarkets & MarketingPharmaceuticalTakeda PharmaceuticalTakelda

1 to 25 of 28 results

Back to top